Positron emission tomography in the diagnosis and treatment management of tuberculosis

Current Pharmaceutical Design

Volumn 17, Issue 27, 2011, Pages 2875-2880

  Kosterink, J G W ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Diagnosis; FDG; Positron emission tomography; Tuberculosis

Indexed keywords

CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

DIAGNOSTIC TEST; DISEASE SEVERITY; LUNG INFECTION; MYCOSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; THORAX RADIOGRAPHY; TUBERCULOMA; TUBERCULOSIS;

EID: 80053487231     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797470183     Document Type: Review

References (72)

1. Ahmad S, Mokaddas E. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Respir Med 2009; 103: 1777-90.
2. Long R. Smear-negative pulmonary tuberculosis in industrialized countries. Chest 2001; 120: 330-4.
3. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician 2005; 72: 1761-8.
4. Mendelson M. Diagnosing tuberculosis in HIV-infected patients: challenges and future prospects. Br Med Bull 2007; 81-82: 149-65.
5. Lee HS, Oh JY, Lee JH, et al. Response of pulmonary tuberculomas to anti-tuberculous treatment. Eur Respir J 2004; 23: 452-5.
6. De Backer A, Mortelé K, De Keulenaer B, Parizel P. Tuberculosis: epidemiology, manifestations and the value of medical imaging in diagnosis. JBR-BTR 2006; 89: 243-50.
7. Parron M, Torres I, Pardo M, et al. The halo sign in computed tomography images: differentiations and correlation with pathology findings. Arch Bronco-neumol 2008; 44: 386-92.
8. Bell GI, Burant CF, Tekeda J, Gould GW. Structure and function of mammalian facilitative sugar transporters. J Biol Chem 1993; 268: 19161-4.
9. Pauwels EK, Ribeiro MJ, Stoot JH, McCready VR, Bourguignon M, Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 1998; 25: 317-22
10. Zhuang H, Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002; 32: 47-59.
11. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis. Global trends and interactions with the HIV epidemic. Arch Int Med 2003; 163: 1009-21.
12. 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med 2002; 43: 871-5.
13. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996; 37: 943-8.
14. Gambhir SS, Shepherd JE, Shah BD, et al. Analytical decision model for the cost-effectiveness management of solitary pulmonary nodules. J Clin Oncol 1998; 16: 3113-25.
15. Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: Findings in 10 cases. Radiology 2000; 216: 117-21.
16. Brudin LH, Valind SO, Rhodes CG, et al. Fluorine-18 deoxyglucose uptake in sarcoidosis measured with positron emission tomography. Eur J Nucl Med 1994; 21: 297-305
17. 18F-FDG PET. J NUcl Med 2005; 46: 1819-24.
18. 18F-fluorocholine PET. J Nucl Med 2006; 47: 262-9.
19. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42: 1412-7.
20. Ishizu K, Nakamura S, Shiozaki T, et al. Increasing rate of FDG uptake from early to delayed PET images in lung tumors. J Nucl Med 2000; 41: 76P.
21. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002; 32: 293-312.
22. 18F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 2003; 44: 1775-83.
23. 18F-fluorocholine PET. J Nucl Med 2006; 47: 262-9.
24. 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42: 1412-7.
25. Ishizu K, Nakamura S, Shiozaki T, et al. Increasing rate of FDG uptake from early to delayed PET images in lung tumors. J Nucl Med 2000; 41: 76P.
26. Alavi A, Gupta N, Alberini JL, Hickeson M, Adam LE, Bhargava P, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med 2002; 32: 293-312.
27. 18 F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis. Chest 2003; 124: 893-901.
28. 11C-choline and the tumor size in lung cancer and pulmonary tuberculoma [abstract]. J Nucl Med 2002; 43 (suppl): 76P
29. 11C-choline PET. J Nucl Med 2000; 41: 1507-13.
30. 18F-FDG PET in primary diagnosis and staging of patients with thoracic cancer. J Nucl Med 2002; 43: 167-72.
31. Sathekge M, Maes A, Kgomo M, Stoltz A, Pottel H, van de Wiele C. Impact of FDG PET ont the management of TBC treatment; a pilot study. Nuklearmed 2010; 49: 35-40.
32. 18F-FDG PET to predict response tot first-line tuberculostatics in HIV-associated tuberculosis. J Nucl Med 2011; 52: 880-5.
33. Bulut Y, Michelsen KS, Hayrapetian L, et al. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. J Biol Chem 2005; 280: 20961-7.
34. Taype CA, Shamsuzzaman S, Accinelli RA, Espinoza JR, Shaw MA. Genetic susceptibilitiy to different clinical forms of tuberculosis in the Peruvian population. Infect Genet Evol 2010; 10: 495-504.
35. Jeong YJ, Lee KS. Pulmonary tuberculosis: up-to-date imaging and management. AJR 2008; 191: 834-44.
36. Kubota R, Yamada S, Kubota K, Ishiwata K, et al. Intratumoral distribution of fluorine-18-deoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med. 1992; 1972-80.
37. de Noronha AL, Báfica A, Noguiera L, Barral A, Barral-Netto M. Lung granulomas from mycobacterium tuberculosis/HIV-1 on coinfected patients display decreased in situ TNF production. Pathol Res Pract 2008; 204: 155-61.
38. Hirsch CS, Johnson JK, Okwera A et al. Mechanisms of apoptosis of T-cells in human tuberculosis. J Clin Immunol 2005; 25: 353-64.
39. Sathekge M, Maes A, Kgomo, van de Wiele C. FDG uptake by lymph nodes of HIV patients is inversely related tot CD4 cell count. Nucl Med Commun 2010; 31: 137-40.
40. Sathekge M, Goethals I, Maes A, van de Wiele C. Positron emission tomography in patients suffering from HIV-1. Eur J Nucl Med Mol Imaging 2009; 36: 1176-84.
41. Wallis RS, Vjecha M, Amir Thamasseb M, et al. Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated beta-2-microglobulin HIV-1 associated tuberculosis. J Infect Dis 1993; 167: 43-8.
42. Lederman M, Georges D, Kusner D, et al. Mycobacterium tuberculosis and its purified protein dervative activate expression of the human immunodeficiency virus. J Acquir Immune Defic Sundr 1994; 7: 727-33.
43. Marino S, Kirschner DE. The human immune response to mycobacterium tuberculosis in lung and lymph node. J Theror Biol 2004; 227: 463-86.
44. Dietrich J, Doherty TM. Interaction of mycobacterium tuberculosis with the host: consquences for vaccine development. APMIS 2009; 117: 440-457.
45. Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Physician 2005; 72: 1761-8.
46. Multidrug resistant and extensively drug-resistant TB (M/CDRTD): 2010 Global Report on Surveillance and Response, Geneva, Switzerland: WHO Press: 1-71. WHO/HTM/TB/2010.3.
47. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14: 131-40.
48. Ahmand S, Mokaddas E. Recent advances in the diagnosis and treatment of multidrug-resistant tuberculosis. Respir Med 2009; 103: 1777-90.
49. Long R. Smear-negative pulmonary tuberculosis in industrialized countries. Chest 2001; 120: 330-4.
50. 18F-fluorodeoxyglucose positron emission tomography for diagnosing disease activity and monitoring therapeutic response in patients with pulmonary mycobacteriosis. Eur J Nucl Med Mol Imaging 2009; 36: 632-9.
51. Im JG, Itoh H, Shim YS, et al. Pulmonary tuberculosis: CT findings-early active disease and sequential change with antituberculous therapy. Radiology 1993; 186: 653-60.
52. Primack SL, Logan PM, Hartman TE, Lee KS, Müller NL. Pulmonary tuberculosis and Mycobacterium avium-intracellulare: a comparison of CT findings. Radiology 1995; 194: 413-7.
53. Elizabeth H, Moore MD. Atypical mycobacterial infection in the lung: CT appearance. Radiology 1993; 187: 777-82.
54. Chan W, Chia M, Lee LK, Macfayen DM. Bacteriological measures for the detection of cases of pulmonary tuberculosis. Bull WHO 1971; 45: 551-8.
55. Goo J.M, Im J.G, Do K.H, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000; 216: 117-21.
56. Patz EF, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evalutation sith F-18-fluorodeoxyglucose PET scanning. Radiology 1993; 188: 487-90.
57. Demura Y, Tsuchida T, Ishizaki T, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003; 44: 540-8.
58. Kim IJ, Lee JS, Kim SJ, et al. Double-fase 18F-FDG PET-CT for determination of pulmonary tuberculoma activity. Eur J Nucl Med Mol Imaging 2008; 35: 808-914.
59. Bandoh S, Fujita J, Ueda Y, et al. Uptake of fluorine-18- fluorodeoxyglucose in pulmonary Mycobacterium avium complex infection. Intern Med 2003; 42: 726-9.
60. Pratt PC. Pathology of tuberculosis. Semin Roentgenol 1970; 14: 196-203.
61. Sumartojo E. When tuberculosis treatment fails. A social behavioral account of patient adherence. Am Rev Respir Dis 1993; 147: 1311-20.
62. Lee HS, Oh JY, Lee JH, et al. Response of pulmonary tuberculosis to anti-tuberculous treatment. Eur Respir J 2004; 23: 452-5.
63. Hofmeyr A, Lau WF, Slavin MA. Mycobacterium tuberculosis infection in patients with cancer, the role of 18-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring treatment response. Tuberculosis 2007; 87: 459-63.
64. Park IN, Ryu JS, Shim TS. Evaluation of therapeutic response of tuberculoma using F-18 FDG positron emission tomography. Clin Nucl Med 2008; 33: 1-3.
65. Kubota R, Kubota K, Yamada S, Tada M. Ido T, Tamahashi N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J Nucl Med 1994; 35: 104-12.
66. Miller WT. Spectrum of pulmonary nontuberculous mycobacterial infection. Radiology 1994; 191: 343-50.
67. Kuhlman JE, Deutsch JH, Fishman EK, Siegelman SS. CT features of thoracic mycobacterial disease. Radiographics 1990; 10: 413-31.
68. Nakamoto Y, Higashi T, Kubota R, et al. Delayed 18F-fluoro-2- deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000; 89: 2547-54.
69. Hamberg RM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35: 1308-12.
70. Hustinx R, Smith RJ, Benard F, et al. Dual time point fluorine-18- fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26: 1345-8.
71. Wang YH, Lin AS, Lai YF, Chao TY, Liu JW, Ko SF. The high value of high resolution computed tomography in predicting the activity of pulmonary tuberculosis. Int j Tuberc Lung Dis 2003; 7: 563-8.
72. Tateishi U, Kusumoto M, Akiyama, et al. Role of contractenhanced dynamic CT in the diagnosis of active tuberculoma. Chest 2002; 122: 1280-4.